Skip to content
Screener

MeiraGTx Holdings plc MGTX Financing Cash Flow

Financing Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Opus Genetics logo
Opus GeneticsIRD
$27.6M+34.8%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$323.74M
Prime Medicine logo
Prime MedicinePRME
$361K+83.2%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$11.48M

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.18B+85.4%
Enterprise value$1.18B+71.1%
P/S14.9×-2.0×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: MeiraGTx Holdings plc’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060739
Line itemFor the Three-Month Periods Ended March 31, 2026For the Three-Month Periods Ended March 31, 2025
Proceeds from the issuance of ordinary shares14,0274,482
Issuance costs in connection with ordinary shares(35)(12)
Payment for treasury shares(18,193)
Net cash (used in) provided by financing activities(10,113)1,713
Net increase (decrease) in cash, cash equivalents and restricted cash5,439(36,825)
Effect of exchange rate changes on cash, cash equivalents and restricted cash126(233)
Cash, cash equivalents and restricted cash at beginning of the period68,193105,668
Cash, cash equivalents and restricted cash at end of the period$73,758$68,610

Item 1. Financial Statements (Unaudited)

FAQ

What is MeiraGTx Holdings plc's financing cash flow?
MeiraGTx Holdings plc (MGTX) reported financing cash flow of -$10.11M in Q1 2026.
How has MeiraGTx Holdings plc's financing cash flow changed year-over-year?
MeiraGTx Holdings plc's financing cash flow decreased by 690.4% year-over-year, from $1.71M to -$10.11M.
What is the long-term trend for MeiraGTx Holdings plc's financing cash flow?
Over 4 years (2021 to 2025), MeiraGTx Holdings plc's financing cash flow has grown at a 64.4% compound annual growth rate (CAGR), from $1.71M to $12.49M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about MeiraGTx Holdings plc's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude